A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

NCT01892345 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica
Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: Eculizumab
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.